Figure 7. PGE2-induced NLRP3 inflammasome inhibition requires higher doses in CAPS patients.
(A) PBMCs from four healthy subjects were treated with LPS (1 μg/ml) for 3 h in complete medium, followed by treatment with the indicated doses of PGE2 or vehicle (EtOH) and ATP (2 mM) or alum (400 μg/ml) for 30 min in serum-free medium. Supernatants and lysates were collected for WB. (B) PBMCs from five CAPS patients with designated mutations in NLRP3 were treated with LPS (1 μg/ml) for 3 h in complete medium, followed by treatment with indicated doses of PGE2 or vehicle (EtOH) for 30 min in serum-free medium. Supernatants and lysates were collected for WB.